Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: Lipoprotein a therapeutics, understanding the pipeline
Logo

American Heart Association

  121
  0

Final ID:

Discussant: Lipoprotein a therapeutics, understanding the pipeline

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
  • Goldberg, Anne  ( Washington Univ School of Medicine , St Louis , Missouri , United States )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now) | Anne Goldberg: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:IONIS:Active (exists now) ; Consultant:NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Bio89:Active (exists now) ; Research Funding (PI or named investigator):Regeneron:Past (completed) ; Research Funding (PI or named investigator):NewAmsterdam:Active (exists now) ; Research Funding (PI or named investigator):Esperion:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):IONIS:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) ; Research Funding (PI or named investigator):Amarin:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Nicholls Stephen, Brunham Liam, Wuerdeman Erin, Neild Annie, Kling Douglas, Hsieh Andrew, Ference Brian, Laufs Ulrich, Banach Maciej, Mehran Roxana, Catapano Alberico, Nelson Adam, Davidson Michael, Ditmarsch Marc, Kastelein John, Ballantyne Christie, Ray Kausik, Navar Ann Marie, Nissen Steven, Goldberg Anne

Discussant: CETP inhibition-is it time for a revival?

Watson Karol

More abstracts from these authors:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

Tokgozoglu Lale

You have to be authorized to contact abstract author. Please, Login
Not Available